Organization Overview
Historical Acquisition Tree
Alternative names
burosumab-twza (crysvita) (2018 NDA)
triheptanoin (Dojolvi) (2020 NDA)
vestronidase alfa-vjbk (mepsevii) (2017 NDA)
Key: Ultragenyx Inc. (7) Acquired (3)
Amyotrophic Lateral Sclerosis (Phase 2)
Angelman Syndrome (Phase 2)
Carbohydrate Metabolism, Inborn Errors (Phase 3)
Chronic Pain (Phase 3)
Disease (Phase 2)
Distal Myopathies (Phase 3)
Familial Hypophosphatemic Rickets (Phase 3)
Glycogen Storage Disease (Phase 2)
Glycogen Storage Disease Type I (Phase 1)
Glycogen Storage Disease Type III (Phase 2)
Glycogen Storage Disease Type IV (Phase 2)
Glycogen Storage Disease Type VII (Phase 2)
Hemophilia A (Phase 2)
Huntington Disease (Phase 2)
Hypophosphatemia (Phase 3)
Metabolic Diseases (Phase 1)
Motor Neuron Disease (Phase 2)
Movement Disorders (Phase 3)
Mucopolysaccharidoses (Phase 3)
Mucopolysaccharidosis VII (Phase 3)
Muscular Diseases (Phase 3)
Neoplasms, Connective Tissue (Phase 2)
Nervous System Diseases (Phase 2)
Nevus (Phase 4)
Nevus, Sebaceous of Jadassohn (Phase 4)
Osteomalacia (Phase 3)
Rett Syndrome (Phase 2)
Rickets (Phase 3)
Rickets, Hypophosphatemic (Phase 3)
Syndrome (Phase 4)
